aTyr Pharma Statistics
Share Statistics
aTyr Pharma has 89M
shares outstanding. The number of shares has increased by 28.76%
in one year.
| Shares Outstanding | 89M |
| Shares Change (YoY) | 28.76% |
| Shares Change (QoQ) | 5.86% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 203 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 11.69M, so 13.16% of the outstanding
shares have been sold short.
| Short Interest | 11.69M |
| Short % of Shares Out | 13.16% |
| Short % of Float | 16.06% |
| Short Ratio (days to cover) | 10.96 |
Valuation Ratios
The PE ratio is -4.2 and the forward
PE ratio is -6.66.
aTyr Pharma's PEG ratio is
0.49.
| PE Ratio | -4.2 |
| Forward PE | -6.66 |
| PS Ratio | 1143.94 |
| Forward PS | 0.7 |
| PB Ratio | 3.84 |
| P/FCF Ratio | -3.89 |
| PEG Ratio | 0.49 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for aTyr Pharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.48,
with a Debt / Equity ratio of 0.19.
| Current Ratio | 5.48 |
| Quick Ratio | 5.48 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | -0.2 |
| Debt / FCF | -0.19 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $4,196.43 |
| Profits Per Employee | $-1,143,267.86 |
| Employee Count | 56 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is 0.79, so aTyr Pharma's
price volatility has been higher than the market average.
| Beta | 0.79 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 3.31 |
| 200-Day Moving Average | 3.02 |
| Relative Strength Index (RSI) | 61.12 |
| Average Volume (20 Days) | 1,497,149 |
Income Statement
In the last 12 months, aTyr Pharma had revenue of 235K
and earned -64.02M
in profits. Earnings per share was -0.86.
| Revenue | 235K |
| Gross Profit | -1.3M |
| Operating Income | -67.91M |
| Net Income | -64.02M |
| EBITDA | -66.37M |
| EBIT | -67.91M |
| Earnings Per Share (EPS) | -0.86 |
Full Income StatementBalance Sheet
The company has 11.05M in cash and 13.28M in
debt, giving a net cash position of -2.23M.
| Cash & Cash Equivalents | 11.05M |
| Total Debt | 13.28M |
| Net Cash | -2.23M |
| Retained Earnings | -532.05M |
| Total Assets | 97.25M |
| Working Capital | 72.59M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -69.12M
and capital expenditures -65K, giving a free cash flow of -69.18M.
| Operating Cash Flow | -69.12M |
| Capital Expenditures | -65K |
| Free Cash Flow | -69.18M |
| FCF Per Share | -0.93 |
Full Cash Flow StatementMargins
Gross margin is -555.32%, with operating and profit margins of -28899.57% and -27243.83%.
| Gross Margin | -555.32% |
| Operating Margin | -28899.57% |
| Pretax Margin | -27243.4% |
| Profit Margin | -27243.83% |
| EBITDA Margin | -28244.26% |
| EBIT Margin | -28899.57% |
| FCF Margin | -29440% |
